BRD4 and leukemia: Given that CDK7 inhibitors have been shown to suppress pro-oncogenic transcription by targeting enhancers in tumor cells30–35, we envisioned that dual inhibition of BRD4 and CDK7 might synergize to suppress the growth of BETi-resistant leukemia cells to overcome resistance.